Skip to main content
Log in

Twice Daily Fractionated Dose Administration of Prednisolone Compared to Standard Once Daily Administration to Patients with Glomerulonephritis or with Kidney Transplants*

Zweimal täglich fraktionierte Verabreichung von Prednisolon im Vergleich zur einmal täglichen Standarddosierung bei Patienten mit Glomerulonephritis oder nach Nierentransplantation

  • ORIGINALARBEIT
  • Published:
Medizinische Klinik Aims and scope Submit manuscript

Abstract

Background:

Pharmacokinetic half-life of prednisolone is 2–3 h, indicating short pharmacodynamic effect duration. Therefore, the fractionated twice daily administration of prednisolone might be favorable.

Patients and Methods:

A 6-month observational study was conducted in a total of 51 patients, 35 with glomerulonephritis and 16 with kidney transplants. Low-dose and long-term prednisolone was given twice daily to 37 patients and once daily to 14 patients.

Results:

The median dose (first – third quartile) for fractionated prednisolone was 2 × 1.25 mg/day (2.5 – 2.6) and significantly lower (p = 0.008) than the once daily standard dose of 1 × 4.0 mg/day (2.5 – 5.0). The number of comedications was also significantly lower in the fractionated dose group: 1.0 co-immunosuppressant (0.0 – 1.0) compared to 1.5 drugs (0.25 – 2.0) such as cyclosporine and/or mycophenolate (p = 0.017), and 0.0 antidiabetics (0.0 – 0.0) versus 0.0 drugs (0.0 – 0.75) such as gliquidone (p = 0.032). The fall in proteinuria was significant in the fractionated dose group with –0.12 g/l (–0.4 – 0.0) versus +0.08 g/l (–0.04 – +0.24) in controls (p = 0.008).

Conclusion:

Twice daily fractionated administration of prednisolone allows a lower daily dose (total 2.5 mg/day), and appears to be as efficient but less diabetogenic compared to the standard once daily dosing (4.0 mg/day).

Zusammenfassung

Hintergrund:

Die pharmakokinetische Halbwertszeit von Prednisolon beträgt nur 2–3 h. Dies weist auf eine kurze pharmakodynamische Wirkdauer hin. Deshalb könnte die fraktionierte zweimal tägliche Dosierung für den immunsuppressiven Effekt von Prednisolon vorteilhaft sein.

Patienten und Methodik:

Über 6 Monate wurde eine Beobachtungsstudie bei 51 Patienten durchgeführt; 35 hatten eine Glomerulonephritis, und 16 waren nierentransplantiert. Die niedrigdosierte Prednisolonerhaltungstherapie wurde bei 37 Patienten zweimal am Tag und bei 14 Patienten einmal täglich fraktioniert gegeben.

Ergebnisse:

Der Median (erste – dritte Quartile) der fraktionierten Dosis betrug 2 × 1,25 mg/Tag (2,5 – 2,6) und war signifikant geringer (p = 0,008) als die Standarddosis von 1 × 4,0 mg/Tag (2,5 – 5,0). Die Zahl der Begleitmedikamente war bei fraktionierter Dosierung ebenfalls signifikant geringer: 1,0 Koimmunsuppressiva (0,0 – 1,0) versus 1,5 Medikamente (0,25 – 2,0) wie Ciclosporin und/oder Mycophenolat (p = 0,017) und 0,0 Antidiabetika (0,0 – 0,0) versus 0,0 Präparate (0,0 – 0,75) wie Gliquidon (p = 0,032). Bei fraktionierter Prednisolondosierung fiel die Proteinurie über 6 Monate mit –0,12 g/l (–0,4 – 0,0) im Vergleich zu +0,08 g/l (–0,04 – +0,24) bei der einmal täglichen Standarddosierung signifikant ab (p = 0,008).

Schlussfolgerung:

Die fraktionierte zweimal tägliche Verabreichung von Prednisolon erlaubt es, eine geringere Tagesdosis zu geben (insgesamt 2,5 mg/Tag). Sie scheint im Vergleich zur einmal täglichen Standarddosierung (4,0 mg/Tag) zumindest ebenso wirksam, aber weniger diabetogen zu sein.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Amsterdam A, Tajima K, Sasson R. Cell-specific regulation of apoptosis by glucocorticoids: implication to their anti-inflammatory action. Biochem Pharmacol 2002;64:843–50.

    Article  PubMed  CAS  Google Scholar 

  2. Kawasaki Y, Suzuki J, Sakai N, et al. Evaluation of T helper-1/-2 balance on the basis of IgG subclasses and serum cytokines in children with glomerulonephritis. Am J Kidney Dis 2004;44:42–9.

    Article  PubMed  CAS  Google Scholar 

  3. Game DS, Lechler RI. Pathways of allorecognition: implications for transplantation tolerance. Transpl Immunol 2002;10:101–8.

    Article  PubMed  CAS  Google Scholar 

  4. Obata F, Yoshida K, Ohkubo M, et al. Contribution of CD4+ and CD8+ T cells and interferon-gamma to the progress of chronic rejection of kidney allografts: the Th1 response mediates both acute and chronic rejection. Transpl Immunol 2005;14:21–5.

    Article  PubMed  CAS  Google Scholar 

  5. Segerer S, Cui Y, Eitner F, et al. Expression of chemokines and chemokine receptors during human renal transplant rejection. Am J Kidney Dis 2001;37:518–31.

    Article  PubMed  CAS  Google Scholar 

  6. Kuroda M, Sasamura H, Shimizu-Hirota R, et al. Glucocorticoid regulation of proteoglycan synthesis in mesangial cells. Kidney Int 2002;62:780–9.

    Article  PubMed  CAS  Google Scholar 

  7. Rops AL, van der Vlag J, Lensen JF, et al. Heparan sulfate proteoglycans in glomerular inflammation. Kidney Int 2004;65:768–85.

    Article  PubMed  CAS  Google Scholar 

  8. Ekstrand A, Schalin-Jantti C, Lofman M, et al. The effect of (steroid) immunosuppression on skeletal muscle glycogen metabolism in patients after kidney transplantation. Transplantation 1996;61:889–93.

    Article  PubMed  CAS  Google Scholar 

  9. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002;96:23–43.

    Article  PubMed  CAS  Google Scholar 

  10. Kelly JJ, Tam SH, Williamson PM, et al. Decreased threshold for the nitric oxide donor glyceryl trinitrate in cortisol-induced hypertension in humans. Clin Exp Pharmacol Physiol 2007;34:1317–8.

    Article  PubMed  CAS  Google Scholar 

  11. Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci 2002;966:73–81.

    Article  PubMed  CAS  Google Scholar 

  12. Agusti C, Rano A, Filella X, et al. Pulmonary infiltrates in patients receiving long-term glucocorticoid treatment: etiology, prognostic factors, and associated inflammatory response. Chest 2003;123:488–98.

    Article  PubMed  CAS  Google Scholar 

  13. Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet 2003;362:1828–38.

    Article  PubMed  CAS  Google Scholar 

  14. Czock D, Keller F, Rasche FM, et al. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 2005;44:61–98.

    Article  PubMed  CAS  Google Scholar 

  15. Hodson E, Willis N, Craig J. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev 2007;4:CD001533. (PubMed PMID: 17943754).

    PubMed  Google Scholar 

  16. Oosterhuis B, ten Berge RJ, Sauerwein HP, et al. Pharmacokinetic-pharmacodynamic modeling of prednisolone-induced lymphocytopenia in man. J Pharmacol Exp Ther 1984;229:539–46.

    PubMed  CAS  Google Scholar 

  17. Keller F, Hemmen T, Schoneshofer M, et al. Pharmacokinetics of methylprednisolone and rejection episodes in kidney transplant patients. Transplantation 1995;60:330–3.

    Article  PubMed  CAS  Google Scholar 

  18. Reiss WG, Slaughter RL, Ludwig EA, et al. Steroid dose sparing: pharmacodynamic responses to single versus divided doses of methylprednisolone in man. J Allergy Clin Immunol 1990;85:1058–66.

    Article  PubMed  CAS  Google Scholar 

  19. Uhl A, Czock D, Boehm BO, et al. Pharmacokinetics and pharmacodynamics of methylprednisolone after one bolus dose compared with two dose fractions. J Clin Pharm Ther 2002;27:281–7.

    Article  PubMed  CAS  Google Scholar 

  20. Pozzi C, Bolasco PG, Fogazzi GB, et al. Corticosteroids in IgA nephropathy: a randomised con trolled trial. Lancet 1999;353:883–7.

    Article  PubMed  CAS  Google Scholar 

  21. Dumler F, Levin NW, Szego G, et al. Long-term alternate day steroid therapy in renal transplantation. A controlled study. Transplantation 1982;34:78–82.

    Article  PubMed  CAS  Google Scholar 

  22. Sullivan FM, Swan IR, Donnan PT, et al. Early treatment with prednisolone or acyclovir in Bell’s palsy. N Engl J Med 2007;357:1598–607.

    Article  PubMed  CAS  Google Scholar 

  23. Wissing KM, Broeders N, Moreno-Reyes R, et al. A controlled study of vitamin D3 to prevent bone loss in renal-transplant patients receiving low doses of steroids. Transplantation 2005;79:108–15.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Frieder Keller.

Additional information

* The paper was presented as abstract at the GfN (Society of Nephrology) meeting, Munich, Germany, September 22–25, 2007.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Decker, S.O., Keller, F., Mayer, J. et al. Twice Daily Fractionated Dose Administration of Prednisolone Compared to Standard Once Daily Administration to Patients with Glomerulonephritis or with Kidney Transplants*. Med Klin 104, 429–433 (2009). https://doi.org/10.1007/s00063-009-1091-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00063-009-1091-x

Key Words:

Schlüsselwörter:

Navigation